Dietary Antioxidants During Cancer Chemotherapy: Impact on Chemotherapeutic Effectiveness and Development of Side Effects

10.1016/0005-2760(79)90249-2

10.1016/0304-3835(82)90048-9

Chajes V, 1995, Breast Cancer Res Treat, 34, 199, 10.1007/BF00689711

Morisaki N, 1984, Lipids, 19, 381, 10.1007/BF02537399

Gavino VC, 1981, J Lipid Res, 22, 763, 10.1016/S0022-2275(20)37347-8

Cornwell DG, 1979, Lipids, 14, 194, 10.1007/BF02533871

Miller JS, 1980, Lab Invest, 42, 495

Morisaki N, 1982, Artery, 11, 88

Morisaki N, 1982, Lipids, 17, 893, 10.1007/BF02534584

Huttner JJ, 1977, Science, 197, 289, 10.1126/science.877555

Gonzalez MJ, 1991, Carcinogenesis, 12, 1231, 10.1093/carcin/12.7.1231

Gonzalez MJ, 1993, Lipids, 28, 827, 10.1007/BF02536237

Shao Y, 1995, Lipids, 30, 1035, 10.1007/BF02536289

Lash ED, 1966, Arch Biochem Biophys, 115, 332, 10.1016/0003-9861(66)90283-9

Gravela E, 1975, Cancer Res, 35, 3041

Cheeseman, KH, Collins, M, Proudfoot, K, Slater, TF, Burton, GW, etal: Studies on lipid peroxidation in normal and tumour tissues. The Novikoff rat liver tumour. Biochem J 235, 507-514, 1986.

Cheeseman, KH, Emery, S, Maddix, SP, Slater, TF, Burton, GW, etal: Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour. Biochem J 250, 247-252, 1988.

Utsumi K, 1965, Biochim Biophys Acta, 105, 368, 10.1016/S0926-6593(65)80160-6

Player TJ, 1979, Br J Cancer, 39, 773, 10.1038/bjc.1979.131

Gauchez AS, 1995, Biol Trace Elem Res, 47, 103, 10.1007/BF02790106

Faber M, 1995, Biol Trace Elem Res, 47, 117, 10.1007/BF02790108

Wiseman, H, and Halliwell, B: Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression of cancer. Biochem J 313, 17-29, 1996.

10.1023/A:1008407014084

Clemens MR, 1990, Am J Clin Nutr, 51, 216, 10.1093/ajcn/51.2.216

10.1016/0891-5849(95)02187-6

Ladner C, 1989, Cancer Chemother Pharmacol, 25, 210, 10.1007/BF00689585

Durken M, 1995, Bone Marrow Transplant, 15, 757

Hunnisett A, 1995, Biol Trace Elem Res, 47, 125, 10.1007/BF02790109

10.1016/0891-5849(96)00041-X

10.1016/0891-5849(90)90139-A

Look MP, 1994, Chemotherapy, 40, 8, 10.1159/000239163

Subramaniam S, 1993, Med Sci Res, 21, 79

10.1016/0163-7258(90)90088-J

Clemens MR, 1997, Wien Klin Wochenschr, 109, 771

Burger RM, 1986, J Biol Chem, 261, 15955, 10.1016/S0021-9258(18)66659-1

Levine EG, 1992, Semin Oncol, 19, 47

10.1016/0140-6736(91)90490-G

Guyton KZ, 1993, Br Med Bull, 49, 523, 10.1093/oxfordjournals.bmb.a072628

Alberts DS, 1978, Biomedicine, 29, 189

10.1016/0277-5379(82)90215-2

10.1038/nm1197-1233

Prasad KN, 1980, Proc Soc Exp Biol Med, 164, 158, 10.3181/00379727-164-40840

Perez-Ripoll EA, 1986, J Urol, 136, 529, 10.1016/S0022-5347(17)44937-8

Prasad KN, 1994, Nutr Cancer, 22, 233, 10.1080/01635589409514349

Guthrie, N, Gapor, A, Chambers, AF, and Carroll, KK: Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination.J Nutr127, 544S-548S, 1997.

10.1016/0277-5379(88)90077-6

Myers CE, 1977, Science, 197, 165, 10.1126/science.877547

Sonneveld P, 1978, Cancer Treat Rep, 62, 1033

Yu W, 1999, Nutr Cancer, 33, 26, 10.1080/01635589909514744

Guthrie, N, Gapor, A, Chambers, AF, and Carroll, KK: Effect of palm oil tocotrienols on epidermal growth factor receptor protein tyrosine kinase activity in human breast cancer cells (abstr). FASEB J 12, A657, 1998.

Okamoto K, 1985, J Nutr Sci Vitaminol, 31, 129, 10.3177/jnsv.31.129

Lenzhofer R, 1983, Experientia, 39, 62, 10.1007/BF01960629

Yamanaka N, 1979, Cancer Chemother Pharmacol, 3, 223, 10.1007/BF00254735

Wang YM, 1980, Cancer Res, 40, 1022

Milei, J, Boveris, A, Llesuy, S, Molina, HA, Storino, R, etal: Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am Heart J 111, 95-102, 1986.

Hermansen K, 1986, Acta Pharmacol Toxicol, 58, 31, 10.1111/j.1600-0773.1986.tb00066.x

Mimnaugh EG, 1979, Toxicol Appl Pharmacol, 49, 119, 10.1016/0041-008X(79)90284-9

Lubawy WC, 1979, Res Commun Chem Pathol Pharmacol, 24, 401

Myers CE, 1976, Cancer Treat Rep, 60, 961

Shinozawa, S, Gomita, Y, and Araki, Y: Effect of high dose alpha-tocopherol and alpha-tocopherol acetate pretreatment in adriamycin (doxorubicin)-induced toxicity and tissue distribution. Physiol Chem Phys Med NMR 20, 329-335, 1988.

Breed JGS, 2033, Cancer Res, 40, 2038

Van Vleet JF, 1980, Am J Pathol, 99, 13

Van Vleet JF, 1980, Cancer Treat Rep, 64, 315

Trizna Z, 1992, Anticancer Res, 12, 325

Trizna Z, 1993, Cancer Detect Prev, 17, 575

10.1016/0027-5107(95)00017-D

Sugihara K, 1986, Jpn J Pharmacol, 40, 353, 10.1254/jjp.40.353

Lenzhofer R, 1983, J Cancer Res Clin Oncol, 106, 143, 10.1007/BF00395393

Buhner R, 1980, Klin Wochenschr, 58, 747, 10.1007/BF01478464

Legha, SS, Wang, YM, Mackay, B, Ewer, M, Hortobagyi, GN, etal: Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann NY Acad Sci 393, 411-418, 1982.

Weitzman SA, 1980, Curr Ther Res, 28, 682

Perez JE, 1986, Cancer Treat Rep, 70, 1213

10.1016/0002-9343(92)90744-V

10.1016/0304-3835(96)04212-7

Prasad, KN, Sinha, PK, Ramanujam, M, and Sakamoto, A: Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA 76, 829-832, 1979.

Chiang, CD, Song, EJ, Yang, VC, and Chao, CCK: Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung cancer cells. Biochem J 301, 759-764, 1994.

Taper HS, 1987, Int J Cancer, 40, 575, 10.1002/ijc.2910400424

Moore C, 1979, Pharmacologist, 21, 233

Shimpo, K, Nagatsu, T, Yamada, K, Sato, T, Niimi, H, etal: Ascorbic acid and adriamycin toxicity.Am J Clin Nutr54, 1298S-1301S, 1991.

Fujita K, 1982, Cancer Res, 42, 309

10.1016/0002-9610(91)90134-Y

Rivas-Olmedo G, 1992, J Toxicol Environ Health, 35, 107, 10.1080/15287399209531599

10.1016/0165-1218(89)90163-8

Solaini G, 1987, Biochem Biophys Res Commun, 147, 572, 10.1016/0006-291X(87)90969-7

Valls V, 1994, Biochem Mol Biol Int, 33, 633

Sugiyama S, 1995, Biochem Mol Biol Int, 36, 1001

Kishi, T, Watanabe, T, and Folkers, K: Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by adriamycin of coenzyme Q10enzymes in mitochondria of the myocardium. Proc Natl Acad Sci USA 73, 4653-4656, 1976.

Iwamoto Y, 1974, Biochem Biophys Res Commun, 58, 633, 10.1016/S0006-291X(74)80465-1

Solaini G, 1985, Drugs Exp Clin Res, 11, 533

Kishi T, 1976, Cancer Treat Rep, 60, 223

Folkers K, 1977, Biochem Biophys Res Commun, 77, 1536, 10.1016/S0006-291X(77)80152-6

Jaenke RS, 1974, Lab Invest, 30, 292

10.1016/0006-2952(76)90278-1

Domae N, 1981, Cancer Treat Rep, 65, 79

Folkers, K, Choe, JY, and Combs, AB: Rescue by coenzyme Q10from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat. Proc Natl Acad Sci USA 75, 5178-5180, 1978.

Combs AB, 1977, Res Commun Chem Pathol Pharmacol, 18, 565

Shaeffer J, 1980, Res Commun Chem Pathol Pharmacol, 29, 309

10.1016/0022-2828(81)90256-X

Shinozawa S, 1984, Acta Med Okayama, 38, 57

10.1016/0378-4274(82)90201-6

10.1016/0098-2997(94)90030-2

Cortes EP, 1978, Cancer Treat Rep, 62, 887

Folkers K, 1985, Drugs Exp Clin Res, 11, 539

10.1007/s002800050134

Mendecki J, 1994, Adv Exp Med Biol, 364, 177

10.1016/0027-5107(92)90052-4

Salvadori DMF, 1994, Mutagenesis, 9, 53, 10.1093/mutage/9.1.53

Bianchi L, 1993, Anticancer Res, 13, 1007

Anderson ME, 1989, Anal Biochem, 183, 16, 10.1016/0003-2697(89)90164-4

10.1016/0305-7372(87)90035-1

Howell SB, 1980, Cancer Treat Rep, 64, 611

Goel, R, Cleary, SM, Horton, C, Kirmani, S, Abramson, I, etal: Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. JNCI 81, 1552-1560, 1989.

10.1016/0009-2797(89)90065-3

Oriana S, 1987, Tumori, 73, 337, 10.1177/030089168707300403

Hamers FPT, 1993, Cancer Res, 53, 544

Jones MM, 1937, Anticancer Res, 9, 1942

Zunino F, 1983, Tumori, 69, 105, 10.1177/030089168306900204

Anderson, ME, Naganuma, A, and Meister, A: Protection against cisplatin toxicity by administration of glutathione ester. FASEB J 4, 3251-3255, 1990.

Yoda Y, 1986, Cancer Res, 46, 2551

Teicher BA, 1988, Cancer, 62, 1275, 10.1002/1097-0142(19881001)62:7<1275::AID-CNCR2820620705>3.0.CO;2-I

Tofanetti O, 1985, Cancer Chemother Pharmacol, 14, 188, 10.1007/BF00258114

Pirovano C, 1992, Tumori, 78, 253, 10.1177/030089169207800408

Bohm S, 1991, Anticancer Res, 11, 1613

Di Re F, 1990, Cancer Chemother Pharmacol, 25, 355, 10.1007/BF00686237

Locatelli MC, 1993, Tumori, 79, 37, 10.1177/030089169307900108

Cozzaglio L, 1990, Tumori, 76, 590, 10.1177/030089169007600617

10.1006/gyno.1994.1252

Cascinu S, 1995, J Clin Oncol, 13, 26, 10.1200/JCO.1995.13.1.26

10.1023/A:1008211226339

Appenroth D, 1993, J Appl Toxicol, 13, 189, 10.1002/jat.2550130309

Miyajima A, 1999, Jpn J Cancer Res, 90, 565, 10.1111/j.1349-7006.1999.tb00784.x

Roller A, 1998, Anticancer Res, 18, 4493

Kline I, 1973, Cancer Chemother Rep, 57, 299

Tolley DA, 1977, Br J Urol, 49, 659, 10.1111/j.1464-410X.1977.tb04548.x

Levy, L, and Vredevoe, DL: The effect of N-acetylcysteine on cyclophosphamide immunoregulation and antitumor activity. Semin Oncol 10 Suppl 1, 7-16, 1983.

Harrison, EF, Fuquay, ME, and Hunter, HL: Effect of N-acetylcysteine on the antitumor activity of cyclophosphamide against Walker-256 carcinosarcoma in rats. Semin Oncol 10 Suppl 1, 25-28, 1983.

Doroshow JH, 1981, J Clin Invest, 68, 1053, 10.1172/JCI110328

Freeman RW, 1980, Toxicol Appl Pharmacol, 54, 168, 10.1016/0041-008X(80)90018-6

Unverferth, DV, Mehegan, JP, Nelson, RW, Scott, CC, Leier, CV, etal: The efficacy of N-acetylcysteine in preventing doxorubicin-induced cardiomyopathy in dogs. Semin Oncol 10 Suppl 1, 2-6, 1983.

10.1016/0002-9149(85)90585-5

Herman EH, 1985, Cancer Res, 45, 276

Slavik, M, and Saiers, JH: Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria. Semin Oncol 10 Suppl 1, 62-65, 1983.

Holoye, PY, Duelge, J, Hansen, RM, Ritch, PS, and Anderson, T: Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Semin Oncol 10 Suppl 1, 66-71, 1983.

Loehrer, PJ, Williams, SD, and Einhorn, LH: N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer. Semin Oncol 10 Suppl 1, 72-75, 1983.

Morgan, LR, Donley, PJ, Harrison, EF, and Hunter, HL: The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung. Semin Oncol 9 Suppl 1, 71-74, 1982.

Myers, C, Bonow, R, Palmeri, S, Jenkins, J, Corden, B, etal: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 10 Suppl 1, 53-55, 1983.

Unverferth, DV, Jagadeesh, JM, Unverferth, BJ, Magorien, RD, Leier, CV, etal: Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. JNCI 71, 917-920, 1983.

Rouse K, 1995, Ann Surg, 221, 420, 10.1097/00000658-199504000-00014

Klimberg, VS, Nwokedi, E, Hutchins, LF, Pappas, AA, Lang, NP, etal: Glutamine facilitates chemotherapy while reducing toxicity. JPEN J Parent Enteral Nutr 16, 83S-87S, 1992.

Klimberg VS, 1992, Arch Surg, 127, 1317, 10.1001/archsurg.1992.01420110063013

Fox, AD, Kripke, SA, De Paula, J, Berman, JM, Settle, RG, etal: Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis. JPEN J Parent Enteral Nutr 12, 325-331, 1988.

Jacobs DO, 1987, Surg Forum, 38, 45

10.1097/00000658-199804000-00006

10.1002/(SICI)1097-0142(19981001)83:7<1433::AID-CNCR22>3.0.CO;2-4

10.1016/S0022-2143(96)90082-7

10.1016/S0959-8049(96)00419-4

Baldew GS, 1990, Cancer Res, 50, 7031

Satoh M, 1992, Cancer Chemother Pharmacol, 30, 439, 10.1007/BF00685594

Ohkawa K, 1988, Br J Cancer, 58, 38, 10.1038/bjc.1988.157

Berry JP, 1984, Cancer Res, 44, 2864

Baldew GS, 1989, Cancer Res, 49, 3020

Coudray C, 1996, Redox Rep, 2, 323, 10.1080/13510002.1996.11747068

Dimitrov NV, 1987, Am J Pathol, 126, 376

Hu YJ, 1997, Biol Trace Elem Res, 56, 331, 10.1007/BF02785304

Wei H, 1993, Nutr Cancer, 20, 1, 10.1080/01635589309514265

Wei H, 1995, Proc Soc Exp Biol Med, 208, 124, 10.3181/00379727-208-43844

10.1016/0006-2952(92)90366-Q

10.1016/0006-2952(90)90153-C

Markovits J, 1989, Cancer Res, 49, 5111

Corbett AH, 1993, J Biol Chem, 268, 14394, 10.1016/S0021-9258(19)85252-3

Robinson MJ, 1993, Biochemistry, 32, 3638, 10.1021/bi00065a016

Okura A, 1988, Biochem Biophys Res Commun, 157, 183, 10.1016/S0006-291X(88)80030-5

10.1016/0145-2126(94)90079-5

Traganos F, 1992, Cancer Res, 52, 6200

Matsukawa Y, 1993, Cancer Res, 53, 1328

Zhou JR, 1998, Cancer Res, 58, 5231

Rauth S, 1997, Br J Cancer, 75, 1559, 10.1038/bjc.1997.268

Pagliacci, MC, Spinozzi, F, Migliorati, G, Fumi, G, Smacchia, M, etal: Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer 29A, 1573-1577, 1993.

10.1016/0304-3835(94)90168-6

Constantinou A, 1990, Cancer Res, 50, 2618

Yanagihara K, 1993, Cancer Res, 53, 5815

Bergamaschi G, 2012, Leukemia, 7, 2018

10.1006/cimm.1993.1287

Knox KA, 1993, Eur J Immunol, 23, 2578, 10.1002/eji.1830231030

Akiyama T, 1987, J Biol Chem, 262, 5592, 10.1016/S0021-9258(18)45614-1

Barnes S, 1996, Adv Exp Med Biol, 401, 87, 10.1007/978-1-4613-0399-2_7

10.1006/bbrc.1998.9751

Shen F, 1999, Anticancer Res, 19, 1657

Adlercreutz H, 1997, Ann Med, 29, 95, 10.3109/07853899709113696

Marverti G, 1996, Clin Cancer Res, 2, 991

Versantvoort CHM, 1993, Br J Cancer, 68, 939, 10.1038/bjc.1993.458

Logvinova AV, 1999, Nutr Cancer, 33, 33, 10.1080/01635589909514745

Bravo L, 1998, Nutr Rev, 56, 317, 10.1111/j.1753-4887.1998.tb01670.x

10.1039/p19960002497

Levy J, 1984, Biochem Biophys Res Commun, 123, 1227, 10.1016/S0006-291X(84)80264-8

Graziani Y, 1983, Eur J Biochem, 135, 583, 10.1111/j.1432-1033.1983.tb07692.x

10.1016/0002-9610(89)90132-3

10.1016/0022-4731(88)90078-7

Suolinna E-M, 1865, Cancer Res, 35, 1872

Yoshida M, 1992, Cancer Res, 52, 6676

Avila MA, 1994, Cancer Res, 54, 2424

Hosokawa N, 1990, Int J Cancer, 45, 1119, 10.1002/ijc.2910450622

Yoshida, M, Sakai, T, Hosokawa, N, Marui, N, Matsumoto, K, etal: The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 260, 10-13, 1990.

Larocca LM, 1990, Br J Haematol, 75, 489, 10.1111/j.1365-2141.1990.tb07787.x

Scambia G, 1990, Br J Cancer, 62, 942, 10.1038/bjc.1990.414

Scambia G, 1991, Cancer Chemother Pharmacol, 28, 255, 10.1007/BF00685531

10.1007/s002800050173

10.1016/0090-8258(92)90484-Z

Hofmann J, 1988, Int J Cancer, 42, 382, 10.1002/ijc.2910420313

Hoffman R, 1989, Br J Cancer, 59, 347, 10.1038/bjc.1989.68

10.1016/0145-2126(92)90176-8

Hofmann J, 1990, Int J Cancer, 45, 536, 10.1002/ijc.2910450327

Schuchter LM, 1997, Oncology, 11, 505

Swain SM, 1997, J Clin Oncol, 15, 1318, 10.1200/JCO.1997.15.4.1318

10.1016/0145-2126(92)90043-7